{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:57:26Z","timestamp":1793120246201,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Lumateperone, a novel antipsychotic drug that was granted by the Food and Drug Administration (FDA) approval in December 2019, remains insufficiently explored for its adverse event profile. This study used the FDA Adverse Event Reporting System (FAERS) database to explore its potential safety issues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study conducted a retrospective analysis of FAERS data from the fourth quarter of 2019 to the third quarter of 2023, extracting reports related to lumateperone. Disproportionality analysis using Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) algorithms was employed to detect signals of adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our research processed 4,777 pertinent AE disclosures related to lumateperone, unveiling 125 signals that satisfied both ROR and BCPNN evaluative benchmarks across 26 System Organ Classes (SOCs). Intriguingly, 108 of these signals were categorized as unanticipated, spotlighting notable psychiatric manifestations such as mania (ROR = 73.82, 95% CI = 57.09\u201395.46; IC = 6.16, IC025 = 4.49), and hypomania (ROR = 34.74, 95% CI = 15.54\u201377.64; IC = 5.10, IC025 = 3.43), alongside non-psychiatric phenomena like urinary retention (ROR = 3.59, 95% CI = 1.80\u20137.19; IC = 1.84, IC025 = 0.18) and serotonin syndrome (ROR = 8.69, 95% CI = 4.81\u201315.72; IC = 3.11, IC025 = 1.45).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This research provides real-world safety data on lumateperone post-marketing and is an important supplement to the information from clinical trial studies. Healthcare professionals should be vigilant for the risk of a manic switch in patients with bipolar depression who are administered lumateperone. More epidemiological studies are needed in the future to explore and further evaluate the risk-benefit issue of lumateperone.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1389814","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:38:36Z","timestamp":1715229516000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"15","author":[{"given":"Dan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/14737175.2023.2236795","article-title":"Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults","volume":"23","author":"Abuelazm","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1399-5618.2003.00083.x","article-title":"Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate","volume":"6","author":"Amsterdam","year":"2004","journal-title":"Bipolar. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.11.010","article-title":"Psychogenic pseudostroke","volume":"23","author":"Behrouz","year":"2014","journal-title":"J. Stroke. Cerebrovasc. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2174\/1389450119666171227225408","article-title":"Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review","volume":"19","author":"Binienda","year":"2018","journal-title":"Curr. Drug. Targets"},{"key":"B6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/026988110101500201","article-title":"Urinary retention caused after fluoxetine-risperidone combination","volume":"15","author":"Bozikas","year":"2001","journal-title":"J. Psychopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1365-2125.2011.04009.x","article-title":"Memory disorders associated with consumption of drugs: updating through a case\/noncase study in the French pharmacovigilance database","volume":"72","author":"Chavant","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291720000161","article-title":"Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase\u00ae","volume":"51","author":"Chr\u00e9tien","year":"2021","journal-title":"Psychol. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.arcped.2017.09.024","article-title":"Acute methotrexate-related neurotoxicity and pseudo-stroke syndrome","volume":"24","author":"Deneux","year":"2017","journal-title":"Arch. Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.9758\/cpn.2016.14.4.388","article-title":"Serotonin syndrome after clomipramine overdose in a child","volume":"14","author":"Direk","year":"2016","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1093\/schbul\/sbaa029.765","article-title":"T205. Lumateperone in the treatment of schizophrenia: evaluation of extrapyramidal and motor symptoms in 4 late-phase clinical trials","volume":"46","author":"Durgam","year":"2020","journal-title":"Schizophr. Bull."},{"key":"B16","first-page":"32","article-title":"Lumateperone for the treatment of schizophrenia","volume":"50","author":"Edinoff","year":"2020","journal-title":"Psychopharmacol. Bull."},{"key":"B17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/nau.22851","article-title":"Linking the evidence between urinary retention and antipsychotic or antidepressant drugs: a systematic review","volume":"35","author":"Faure Walker","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"B18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"B20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States food and drug administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11920-022-01344-1","article-title":"Lumateperone for the treatment of adults with schizophrenia: a systematic review","volume":"24","author":"Jawwad","year":"2022","journal-title":"Curr. Psychiatry. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","article-title":"Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials","volume":"36","author":"Kane","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40265-023-01872-x","article-title":"New pharmacologic approaches to the treatment of bipolar depression","volume":"83","author":"Keramatian","year":"2023","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2174\/157488612803251333","article-title":"Quetiapine induced hypomania: a case report and a review of the literature","volume":"7","author":"Khalil","year":"2012","journal-title":"Curr. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/s1092852900021386","article-title":"Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports","volume":"12","author":"Kohen","year":"2007","journal-title":"CNS Spectr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1358\/dot.2018.54.12.2899443","article-title":"Lumateperone: a new treatment approach for neuropsychiatric disorders","volume":"54","author":"Kumar","year":"2018","journal-title":"Drugs Today(Barc)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.4088\/jcp.v63n1214j","article-title":"A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics","volume":"63","author":"Lu","year":"2002","journal-title":"J. Clin. Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"24932","DOI":"10.52965\/001c.24932","article-title":"Lumateperone tosylate, a selective and concurrent modulator of serotonin, dopamine, and glutamate, in the treatment of schizophrenia","volume":"9","author":"Maini","year":"2021","journal-title":"Health Psychol. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/eb-2014-101948","article-title":"Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy","volume":"18","author":"Malhi","year":"2015","journal-title":"Evid. Based Ment. Health"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature19318","article-title":"Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala","volume":"537","author":"Marcinkiewcz","year":"2016","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"22m14739","DOI":"10.4088\/JCP.22m14739","article-title":"The efficacy of lumateperone in patients with bipolar depression with mixed features","volume":"84","author":"McIntyre","year":"2023","journal-title":"J. Clin. Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.focus.20200051","article-title":"Contrasting typical and atypical antipsychotic drugs","volume":"19","author":"Meltzer","year":"2021","journal-title":"Focus Am Psychiatr. Publ."},{"key":"B35","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform."},{"key":"B36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.euroneuro.2011.09.008","article-title":"Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder","volume":"22","author":"Popovic","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.4088\/jcp.v64n1116d","article-title":"Mania from dose-related ziprasidone augmentation of an SSRI","volume":"64","author":"Privitera","year":"2003","journal-title":"J. Clin. Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1034\/j.1600-0447.2001.00383.x","article-title":"Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders","volume":"104","author":"Ramasubbu","year":"2001","journal-title":"Acta. Psychiatr. Scand."},{"key":"B40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1178646919873925","DOI":"10.1177\/1178646919873925","article-title":"Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions","volume":"12","author":"Scotton","year":"2019","journal-title":"Int. J. Tryptophan Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/medicina55070361","article-title":"Suicide in schizophrenia: an educational overview","volume":"55","author":"Sher","year":"2019","journal-title":"Med. Kaunas."},{"key":"B44","first-page":"52","article-title":"Antipsychotic drug side effect issues in bipolar manic patients","volume":"61","author":"Zarate","year":"2000","journal-title":"J. Clin. Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1389814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:38:39Z","timestamp":1715229519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1389814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":46,"alternative-id":["10.3389\/fphar.2024.1389814"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1389814","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"article-number":"1389814"}}